Show simple item record

dc.contributor.authorHahn, T
dc.contributor.authorPolanczyk, MJ
dc.contributor.authorBorodovsky, A
dc.contributor.authorRamanathapuram, LV
dc.contributor.authorAkporiaye, ET
dc.contributor.authorRalph, SJ
dc.date.accessioned2017-05-03T14:14:58Z
dc.date.available2017-05-03T14:14:58Z
dc.date.issued2013
dc.date.modified2014-03-24T04:41:20Z
dc.identifier.issn1389-2010
dc.identifier.urihttp://hdl.handle.net/10072/52530
dc.description.abstractCytotoxic drugs in cancer therapy are used with the expectation of selectively killing and thereby eliminating the offending cancer cells. If they should die in an appropriate manner, the cells can also release danger signals that promote an immune reaction that reinforces the response against the cancer. The identity of these immune-enhancing danger signals, how they work extra- and intracellularly, and the molecular mechanisms by which some anti-cancer drugs induce cell death to bring about the release of danger signals are the major focus of this review. A specific group of mitocans, the vitamin E analogs that act by targeting mitochondria to drive ROS production and also promote a more immunogenic means of cancer cell death exemplify such anti-cancer drugs. The role of reactive oxygen species (ROS) production and the events leading to the activation of the inflammasome and pro-inflammatory mediators induced by dying cancer cell mitochondria are discussed along with the evidence for their contribution to promoting immune responses against cancer. Current knowledge of how the danger signals interact with immune cells to boost the anti-tumor response is also evaluated.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.format.extent2141878 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoen_US
dc.publisherBentham Science
dc.publisher.placeNetherlands
dc.publisher.urihttp://www.ingentaconnect.com/content/ben/cpb/2013/00000014/00000003/art00010
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom357
dc.relation.ispartofpageto376
dc.relation.ispartofissue3
dc.relation.ispartofjournalCurrent Pharmaceutical Biotechnology
dc.relation.ispartofvolume14
dc.rights.retentionN
dc.subject.fieldofresearchMolecular Targets
dc.subject.fieldofresearchMedical Biotechnology
dc.subject.fieldofresearchPharmacology and Pharmaceutical Sciences
dc.subject.fieldofresearchcode111207
dc.subject.fieldofresearchcode1004
dc.subject.fieldofresearchcode1115
dc.titleUse of Anti-Cancer Drugs, Mitocans, to Enhance the Immune Responses against Tumors
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.rights.copyright© 2013 Bentham Science Publishers. This is the author-manuscript version of this paper. Reproduced in accordance with the copyright policy of the publisher. Please refer to the journal website for access to the definitive, published version.
gro.date.issued2013
gro.hasfulltextFull Text
gro.griffith.authorRalph, Stephen J.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record